A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-08

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Adipose Tissue in Adaptive Responses to Exercise

NCT06053125

Healthy Obesity

ACTIVE_NOT_RECRUITING NA

Regional Fat Depots and Insulin Resistance

NCT01336777

Obesity Insulin Resistance Diabetes Mellitus Type 2

COMPLETED

The Incidence,Factors,and Importance of Brown Adipose Tissue in Chinese Adults

NCT01387438

Obesity

UNKNOWN

Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism

NCT02692885

Brown Adipose Tissue (BAT) Physiology Phenotyping Brown Adipocytes

RECRUITING

Effect of Weight Loss on Cardiovascular Disease Risk Factors in Obese Women

NCT01353001

Obesity Cardiovascular Diseases

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In recent years, the contribution of adipose tissue to obesity-related insulin resistance (IR), diabetes mellitus and cardiovascular disease (CVD) has become clear.In particular, accumulation of damaged cells in obese and aging adipose tissue has been shown to impair adipose tissue function and may thus increase CVD risk. Cellular and molecular alterations in adipose tissue are known to contribute to adipose tissue and systemic insulin resistance, chronic inflammation, and may lead to higher blood pressure. Importantly, any clinical consequences of adipose tissue dysfunction would be compounded by the large amount, and central metabolic role, of adipose tissue in humans. However, there is a gap in our understanding of the OSA-induced changes in the adipose tissue and its implication for development of cardiometabolic disorders.

The aim of this study is to examine the cellular and molecular composition of adipose tissue in obstructive sleep apnea (OSA) subjects in comparison to adipose tissue from healthy individuals. We hypothesize that adipose tissue from OSA subjects will have a higher accumulation of markers of cellular damage with positive p16 and γH2AX. These studies will provide pivotal insights into pathways that may be targeted to reduce cardiometabolic burden in OSA population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea of Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obstructive Sleep Apnea

Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) \>=5

No interventions assigned to this group

Non-Obstructive Sleep Apnea

Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) \< 5

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI ≤40 kg/m2
* Not a current smoker or tobacco user
* Individuals with treated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study
* On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), depression, acid reflux (such as antacids or proton pump inhibitors), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.
* Not pregnant or breast feeding and not intending to become pregnant or breast feed
* Ability to provide written informed consent
* If a subject is on aspirin or any other anti-inflammatory medication but free of known vascular disease and depending on the indication, the study doctor may ask the subject to suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the study. In the event that the subject does not stop the aspirin or other anti-inflammatory medication, they will not be able to participate in the study because of the risk of bleeding during the fat biopsy.

Exclusion Criteria

* Vulnerable study population will be excluded
* Presence of chronic kidney disease (creatinine \>2.5 mg/dL) and/or active cancers
* Pregnancy
* Anemic (hemoglobin \<12 g/dL for men and \<11 g/dL for women)
* Smoking
* Use of chronic medications (statins, anti-inflammatory drugs, angiotensin II receptor blockers (ARBs) and/or angiotensin-converting enzyme (ACE) inhibitors)
* Blood or plasma donation during the past 2 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes